<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245840</url>
  </required_header>
  <id_info>
    <org_study_id>SHP621-303</org_study_id>
    <nct_id>NCT03245840</nct_id>
  </id_info>
  <brief_title>Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents&#xD;
      with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302&#xD;
      extension study. The purpose of this study is to see if BOS is safe and well tolerated over&#xD;
      the long-term in adolescents and adults with EoE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Anticipated">April 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration to 3 days after last study drug administration (up to Month 73)</time_frame>
    <description>Treatment-emergent adverse event is defined as an adverse event (AE) that starts or deteriorates on or after the date of the first dose of BOS and no later than 3 days following the last dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Physical Examinations, Vital Signs and Clinical Laboratory Assessments</measure>
    <time_frame>From start of study drug administration to 3 days after last study drug administration (up to Month 73)</time_frame>
    <description>A change in the value of a clinical laboratory or vital sign assessment can represent an AE if the change is clinically relevant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 2 (Month 12)</measure>
    <time_frame>Baseline and Visit 2 (Month 12)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 4 (Month 24)</measure>
    <time_frame>Baseline and Visit 4 (Month 24)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 6 (Month 36)</measure>
    <time_frame>Baseline and Visit 6 (Month 36)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 8 (Month 48)</measure>
    <time_frame>Baseline and Visit 8 (up to Month 48)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 10 (Month 60)</measure>
    <time_frame>Baseline and Visit 10 (up to Month 60)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density (BMD) For Adolescents Assessed by Dual-Energy X-ray Absorptiometry (DXA) Scan at Visit 12 (Month 72)</measure>
    <time_frame>Baseline and Visit 12 (up to Month 72)</time_frame>
    <description>Dual-energy X-ray absorptiometry (DEXA) scans for determination of BMD will be performed in participants aged 11-17 years, inclusive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 2 (Month 12)</measure>
    <time_frame>Baseline and Visit 2 (Month 12)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 microgram [mcg]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 4 (Month 24)</measure>
    <time_frame>Baseline and Visit 4 (Month 24)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 6 (Month 36)</measure>
    <time_frame>Baseline and Visit 6 (Month 36)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 8 (Month 48)</measure>
    <time_frame>Baseline and Visit 8 (up to Month 48)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 10 (Month 60)</measure>
    <time_frame>Baseline and Visit 10 (up to Month 60)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Adrenocorticotropic Hormone (ACTH) Stimulation Level at Visit 12 (Month 72)</measure>
    <time_frame>Baseline and Visit 12 (up to Month 72)</time_frame>
    <description>Adrenocorticotropic hormone stimulation testing will be performed by measuring the levels of cortisol in the blood following the injection of a synthetic form of ACTH (250 mcg).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Eosinophilic Esophagitis (EoE)</condition>
  <arm_group>
    <arm_group_label>Budesonide Oral Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be initiated on 10 milliliter (mL) of Budesonide oral suspension (0.2 milligram/mL) twice daily up to 72 months (Visit 12) or early termination (ET).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide oral suspension</intervention_name>
    <description>Budesonide oral suspension (BOS) 10 mL twice daily</description>
    <arm_group_label>Budesonide Oral Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant completed the SHP621-302 (NCT02736409) extension study and is considered&#xD;
             by the investigator to potentially benefit from continued BOS investigational&#xD;
             treatment.&#xD;
&#xD;
          -  Participant is able to provide written informed consent (participant, parent or legal&#xD;
             guardian and, as appropriate, participant assent) to participate in the study before&#xD;
             completing any study-related procedures.&#xD;
&#xD;
          -  Females of childbearing potential must agree to continue acceptable birth control&#xD;
             measures (example (e.g.): abstinence, surgically sterile male partner, stable oral&#xD;
             contraceptives, or double-barrier methods) throughout study participation.&#xD;
&#xD;
          -  Participant is willing and has an understanding and ability to fully comply with study&#xD;
             procedures and restrictions as defined in protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has changes in medications or diet during the SHP621-302 (NCT02736409)&#xD;
             study that could affect participation in this continuation study.&#xD;
&#xD;
          -  Participant anticipates using swallowed topical corticosteroid for EoE or systemic&#xD;
             corticosteroid for any condition during the treatment period; any temporary use (less&#xD;
             than or equal to [â‰¤] 7 days) or initiation of new steroid treatment during the study&#xD;
             should be documented and discussed with the medical monitor prospectively but should&#xD;
             be avoided within 4 weeks of the scheduled esophagogastroduodenoscopy (EGDs).&#xD;
&#xD;
          -  Participant anticipates use of Cytochrome P450 3A4 inhibitors (e.g., ketoconazole,&#xD;
             grapefruit juice) during the continuation study.&#xD;
&#xD;
          -  Participant has an appearance at the EGD at the final treatment evaluation visit of&#xD;
             SHP621-302 (NCT02736409) (Visit 8) of an esophageal stricture (high grade), as defined&#xD;
             by the presence of a lesion that does not allow passage of a diagnostic adult upper&#xD;
             endoscope (e.g., with an insertion tube diameter of greater than (&gt;) 9 millimeter&#xD;
             [mm]).&#xD;
&#xD;
          -  Participant has presence of esophageal varices at the EGD at the final treatment&#xD;
             evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.&#xD;
&#xD;
          -  Participant has any current disease of the gastrointestinal tract, aside from EoE,&#xD;
             including eosinophilic gastritis, enteritis, colitis, or proctitis, inflammatory bowel&#xD;
             disease, or celiac disease.&#xD;
&#xD;
          -  Participant has other diseases causing or associated with esophageal eosinophilia,&#xD;
             including hypereosinophilic syndrome, collagen vascular disease, vasculitis,&#xD;
             achalasia, or parasitic infection.&#xD;
&#xD;
          -  Participant has oropharyngeal or esophageal candidiasis that failed to respond to&#xD;
             previous treatment. Diagnosis with oropharyngeal or esophageal candidiasis at or since&#xD;
             the final treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study&#xD;
             is not an exclusion as long as the participant is expected to respond to treatment.&#xD;
&#xD;
          -  Participant has a potentially serious acute or chronic infection or immunodeficiency&#xD;
             condition, including tuberculosis, fungal, bacterial, viral/parasite infection, ocular&#xD;
             herpes simplex, or chicken pox/measles.&#xD;
&#xD;
          -  Participant has upper gastrointestinal bleeding identified at the EGD at the final&#xD;
             treatment evaluation visit (Visit 8) of the SHP621-302 (NCT02736409) study.&#xD;
&#xD;
          -  Participant has evidence of active infection with Helicobacter pylori.&#xD;
&#xD;
          -  Participant has evidence of unstable asthma.&#xD;
&#xD;
          -  Participant is female and pregnant or nursing.&#xD;
&#xD;
          -  Participant has a history of intolerance, hypersensitivity, or idiosyncratic reaction&#xD;
             to budesonide (or any other corticosteroids), or to any other ingredients of the study&#xD;
             medication.&#xD;
&#xD;
          -  Participant has a history or high risk of noncompliance with treatment or regular&#xD;
             clinic visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Pediatric Gastroenterology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut GI</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research LLC</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Center For Digestive Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Teton Research Group</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology of Southern Indiana</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>00211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology PA</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital, Icahn School of Medicine</name>
      <address>
        <city>Astoria</city>
        <state>New York</state>
        <zip>11102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group LLP</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal and Liver Diseases Consultants PC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Endoscopy and Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritas Research Group</name>
      <address>
        <city>Lansdowne Town Center</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Medical Research</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fd84db2bf003ab47062</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

